Resp Flashcards Preview

IPE > Resp > Flashcards

Flashcards in Resp Deck (103):
1

Define vital capacity

Volume of air expired from the lungs from a maximal inspiration using a slow/relaxed manoeuvre

2

Define forced vital capacity

Volume of air that can be forcible expelled from the lungs from a position of maximal inspiration

3

Define forced expiratory volume

volume of air forcibly expelled from the lungs in the first second - following maximal inspiration

4

Pathophysiology of anaphylaxis

Sensitised individual exposed to specific antigen
Immunological response:
– IgE → antigen → mast cell & basophils ‡ → histamine ↑ → body response

5

Features of anaphylaxis

Uritus, urticaria & angioedema, hoarseness, progressing to stridor & bronchial obstruction, wheeze & chest tightness from bronchospasm

6

Management of anaphylaxis

DO NOT DELAY! GET HELP
• Remove trigger, maintain airway, 100% O2
• IM adrenaline 0.5 mg
(Repeat every 5 mins as needed to support CVS)
• IV hydrocortisone 200mg
• IV chlorpheniramine 10 mg
• If hypotensive: lie flat and fluid resuscitate
• Treat bronchospasm: NEB salbutamol
• Laryngeal oedema: NEB adrenaline

7

Severity of asthma exacerbations

Mild:
• No features of severe asthma
• PEFR >75%
Moderate:
• No features of severe asthma
• PEFR 50-75%
Severe (if any one of the following):
• PEFR 33 – 50% of best or predicted
• Cannot complete sentences in 1 breath
• Respiratory Rate > 25/min
• Heart Rate >110/min
Life threatening (if any one of the following):
• PEFR < 33% of best or predicted
• Sats <92% or ABG pO2 < 8kPa
• Cyanosis, poor respiratory effort, near or fully silent
chest
• Exhaustion, confusion, hypotension or arrhythmias
• Normal pCO2
Near Fatal:
• Raised pCO2

8

Acute asthma attack management

ABCDE
Oxygen - aim 94-98%
Salbutamol 5mg NEB (repeat after 15 min
Hydrocortisone 100mg IV (or prednisolone 40mg PO)
Ipratropium bromide 500mcg NEB
Theophyilline (IV amionophylline)
Magnesium sulphate
Escalate care - ITU

Consider IV salbutamol
Life threatening - portable CXR

9

Features of an infective COPD exacerbation

Change in sputum volume / colour
Fever
Raised WCC +/- CRP

10

Management of COPD exacerbation

Oxygen - 24-28% fixed performance face mask. AIm sats 88-92%
Antibiotics (if infective)
Salbutamol NEB
Ipratropium NEB
Steroids - prednisolone 30mg STAT and 7d

Consider IV aminophyline
Consider NIV if pH <7.35
ITU if pH <7.25

11

CURB -65

C Confusion, MMT 2 or more points worse
U Urea > 7.0
R >30/min
B < 90 mm Hg systolic or < 60 mm Hg diastolic 65 Age above 65 years

12

Treatment of pneumonia

ABCDE
If any features of sepsis – immediately treat using sepsis pathway – NO DELAY in initiating IV antibiotics and fluids
Otherwise treat with antibiotics as per CURB-65 score, local pneumonia guidelines and awareness of any patient drug allergies

13

Features of pneumonia

Consolidation on CXR with fever +/- purulent sputum +/ raised
WCC and / or CRP

14

Classification of massive haemoptysis

>240mls in 24 hours OR >100mls / day over consecutive days

15

Management of massive haemoptysis

• ABCDE
• Lie patient on side of suspected lesion (if known) • Oral Tranexamic Acid for 5 days or IV
• Stop NSAID’s / aspirin / anticoagulants
• Antibiotics if any evidence of respiratory tract
infection
• Consider Vitamin K
• CT aortogram – interventional radiologist may be able to undertake bronchial artery embolisation

16

Features of tension pneumothorax

o hypotension
o tachycardia
o deviation of the trachea away from the side of
the pneumothorax
o Mediastinal shift away from pneumothorax

17

Management of tension pneumothorax

- Large bore intravenous cannula into 2nd ICS MCL
- Chest drain into the affected side

18

Symptoms of PE

(and symptoms of massive PE)

– Chest pain (pleuritic)
– SOB
– Haemoptysis
– Low cardiac output followed by collapse (if
Massive PE)

Massive
• hypotension/ imminent cardiac arrest
• signs of right heart strain on CT / Echo
• Consider thrombolysis with IV alteplase

19

Risk factors for PE

Thrombopillia/ antiphospholipid syndrome
Hx PE/VTE
Recent travel
Obstetric - pregnancy/ OCP
Malignancy
Break lower limb/ varicose veins
Old age
Surgery
Immobility
Sex (F)

20

Management of PE

ABCDE
• Oxygen if hypoxic
• Fluid resuscitation (if hypotensive)
• Thrombolysis should be considered if a massive PE
is confirmed on Echo or CT scan
– consider without imaging if there is substantial clinical suspicion and cardiac arrest is imminent
– check for contraindications
• Should be fully anticoagulated

21

Absolute thrombolysis contraindications

Haemorrhagic stroke or Ischaemic stroke < 6 months
CNS neoplasia
Recent trauma or surgery
GI bleed < 1 month
Bleeding disorder
Aortic Dissection

22

Relative thrombolysis contraindications

Warfarin
Pregnancy
Advanced Liver Disease
Infective Endocarditis

23

Complications of thrombolysis

• Bleeding
• Hypotension
• Intracranial haemorrhage / stroke
• Reperfusion arrhythmias
• Systemic embolisation of thrombus
• Allergic reaction

24

Pathophysiology of asthma

Airway epithelial damage – shedding and subepithelial fibrosis, basement membrane thickening
• An inflammatory reaction characterised by eosinophils, T-lymphocytes (Th2) and mast cells. Inflammatory mediators released include histamine, leukotrienes, and prostaglandins
• Cytokines amplify inflammatory response
• Increased numbers of mucus secreting goblet cells
and smooth muscle hyperplasia and hypertrophy
• Mucus plugging in fatal and severe asthma

25

Characteristics of asthma

• Asthma is a chronic inflammatory disease of the airways
• Airway obstruction that is reversible (but not completely so in some subjects), either spontaneously or with treatment
• Increased airway responsiveness (airway narrowing) to a variety of stimuli

26

Differentials of a wheeze

> Acute Asthma Exacerbation
• Bronchitis – viral or bacterial
Other causes of wheeze less likely:
• Pulmonary oedema
• PE
• Vocal cord dysfunction
• Gastro-oesophageal reflux
• Foreign body
• Allergy
• Hyperventilation / psychosocial
• Cardiac disease
• Vasculitides – Churg-Strauss syndrome, polyarteritis nodosa, Granulomatosis with Polyangiitis (Wegener’s granulomatosis)
• Carcinoid syndrome with hepatic metastases – release of HIAA

27

Criteria for safe asthma discharge after exacerbation

• PEFR >75%
• Stop regular nebulisers for 24 hours prior to discharge
• Inpatient asthma nurse review to reassess inhaler
technique and adherence
• Provide PEFR meter and written asthma action plan
• At least 5 days oral prednisolone
• GP follow up within 2 working days
• Respiratory Clinic follow up within 4 weeks
• For severe or worse, consider psychosocial factors

28

Differentials of eosinophilia

• Airways inflammation (asthma or COPD)
• Hayfever / allergies
• Allergic Bronchopulmonary Aspergillosis
• Drugs
• Churg-Strauss / vasculitis
• Eosinophilic Pneumonia
• Parasites
• Lymphoma
• SLE
• Hypereosinophilic syndrome

29

Asthma trigger factors

• Smoking
• Upper respiratory tract infections – mainly viral
• Allergens – pollen, house dust mite, pets
• Exercise – also cold air
• Occupational irritants
• Pollution
• Drugs – aspirin, beta blockers (including eye drops)
• Food and drink – dairy produce, alcohol, orange
juice
• Stress
• Severe asthma – consider inhaled heroin, pre-menstrual, psychosocial aspects

30

NICE definition of COPD

COPD is characterised by airflow obstruction. The airflow obstruction is usually progressive, not fully reversible and does not change markedly over several months. The disease is predominantly caused by smoking.

31

Pathophysiology of COPD

COPD is an umbrella term which encompasses emphysema and chronic bronchitis:
• Mucous gland hyperplasia
• Loss of cilial function
• Emphysema – alveolar wall destruction causing
irreversible enlargement of air spaces distal to the
terminal bronchiole
• Chronic inflammation (macrophages and
neutrophils) and fibrosis of small airways

32

Causes of COPD

> Smoking
• Inherited α-1-antitrypsin deficiency
• Industrial exposure, e.g. soot

33

Members involved in MDT management of COPD

• Physicians
• G.P.’s
• Specialist nurses
• Physiotherapists
• Pharmacists
• Occupational therapists
• Dieticians

34

Outpatient COPD management

• ‘COPD Care Bundle’
• SMOKING CESSATION
• Pulmonary Rehabilitation
• Bronchodilators
• Antimuscarinics
• Steroids
• Mucolytics
• Diet
• LTOT if appropriate
• LUNG VOLUME REDUCTION if appropriate

35

Criteria for long term oxygen therapy in COPD

> pO2 consistently below 7.3 kPa, or below 8 kPa with cor pulmonale
• Patients must be non-smokers and not retain high levels of CO2

36

Reason for pulmonary rehabilitation in COPD

Many COPD patients with COPD avoid exercise and physical activity because of breathlessness
• This may lead to a vicious cycle of increasing social isolation and inactivity leading to worsening of symptoms
• Pulmonary Rehabilitation aims to break this cycle – an MDT 6-12 week programme of supervised exercise, unsupervised home exercise, nutritional advice, and disease education

37

CXR consolidation differentials

Pneumonia
TB (usually upper lobe)
Lung cancer
Lobar collapse (blockage of bronchi)
Haemorrhage

38

Investigations for pneumonia

CXR
FBC, UE, CRP
Sputum culture
Blood culture (if febrile), Serology and urine legionella test (if high CURB65), ABG

39

Pneumonia follow up

• HIV test
• Immunoglobulins
• Pneumococcal IgG serotypes
• Haemophilus influenzae b IgG
• Follow up in clinic in 6 weeks with a repeat CXR to
ensure resolution

40

Causes of non-resolving pneumonia

CHAOS
• Complication – empyema, lung abscess
• Host – immunocompromised
• Antibiotic – inadequate dose, poor oral absorption
• Organism – resistant or unexpected organism not
covered by empirical antibiotics
• Second diagnosis – PE, cancer, organising
pneumonia

41

Clinical features of TB

- fever
- nocturnal sweats
- Weight loss (weeks – months)
- Malaise
- Respiratory TB: cough ± purulent sputum/ haemoptysis, (+/-pleural effusion)
Non-Respiratory TB: Skin (erythema nodosum); Lymphadenopathy; Bone/joint; Abdominal; CNS (meningitis); Genitourinary; Miliary (disseminated); Cardiac (pericardial effusion)

42

Differentials of Haemoptysis

Infection:
• Pneumonia
• Tuberculosis
• Bronchiectasis / CF
• Cavitating lung lesion (often fungal)
Malignancy:
• Lung cancer
• Metastases
Haemorrhage:
• Bronchial artery erosion
• Vasculitis
• Coagulopathy
Others:
• PE

43

Risk factors for TB

Past history of TB
Known history of TB contact
Born in a country with high TB incidence
Foreign travel to country with high incidence of TB
Evidence of immunosuppression–e.g. IVDU, HIV, solid organ transplant recipients, renal failure/ dialysis, malnutrition/ low BMI, DM, alcoholism

44

Management for respiratory TB

ABCDE
CXR
Admit to side room and start infection control
3 x early morning sputum samples (AAFB and TB culture)
FBC,LFT, UE, vit D levles
HIV test
CT chest if CXR not clear
MRI/Spine if milary
Abx for pneumonia if diagnosis not clear
If highly likley TB - start anti-TB therapy (after cultures)
Notify TB nurse specialist (initiate contact tracing etc)
TB cukture can take 6-8 weeks

45

Anti-TB therapy

4 antibiotics for 2 months
(Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) followed by 4 months on two antibiotics (Rifampicin, Isoniazid)
+ Pyridoxine as prophylaxis against peripheral neuropathy

-Dose is weight dependent
- check baseline LFT’s and monitor closely
- Check visual acuity

Compliance is crucial and Directly Observed Therapy (DOT) sometimes used for patients
Provide leaflets on treatment & ensure patient is aware of common and serious SE
Corticosteroids sometimes used, mainly seen in those with TB meningitis

46

Side effects of TB treatment

Rifampicin – Hepatitis, rashes, febrile reaction, orange/red secretions (N.B. contact lenses), many drug interactions including warfarin and OCP

Isoniazid – Hepatitis, rashes, peripheral neuropathy, psychosis

Pyrazinamide – Hepatitis, rashes, vomiting, arthralgia

Ethambutol – Retrobulbar neuritis

47

Definition of bronchiectasis

Chronic dilatation of one or more bronchi. The bronchi exhibit poor mucus clearance and there is predisposition to recurrent or chronic bacterial infection

48

Diagnostic test for bronchiectasis

High Resolution CT

49

Causes of bronchiectasis

• Post infective – whooping cough, TB
• Immune deficiency – Hypogammaglobulinaemia
• Genetic / Mucociliary clearance defects – Cystic
fibrosis, primary ciliary dyskinesia, Young’s syndrome (triad of bronchiectasis, sinusitis, and reduced fertility), Kartagener syndrome (triad of bronchiectasis, sinusitits, and situs inversus)
• Obstruction – foreign body, tumour, extrinsic lymph node
• Toxic insult – gastric aspiration (particularly post lung transplant), inhalation of toxic chemicals/gases
• Allergic bronchopulmonary aspergillosis
• Secondary immune deficiency – HIV, malignancy
• Rheumatoid arthritis
• Associations – inflammatory bowel disease; yellow
nail syndrome

50

Common organisms that cause bronchiectasis

• Haemophilus influenzae
• Pseudomonas aeruginosa
• Moraxella catarrhalis
• Stenotrophomonas maltophilia
• Fungi – aspergillus, candida
• Non-tuberculous mycobacteria
• Less common - Staphylococcus aureus (think about
CF)

51

Management of bronchiectasis

• Treat underlying cause
• Physiotherapy – mucus clearance
• Antibiotics according to sputum cultures /
sensitivities for acute exacerbations and often
chronic suppressive therapy
• Supportive – flu vaccine, bronchodilators if required
• Pulmonary Rehab – MRC Dyspnoea Score >3

52

Definition of CF

CF is an autosomal recessive disease leading to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). This can lead to a multisystem disease (most commonly affecting the respiratory and gastrointestinal systems) characterised by thickened secretions.

53

Diagnostic criteria for CF

One or more of the characteristic phenotypic features -
• Or a history of CF in a sibling
• Or a positive newborn screening test result
And
• An increased sweat chloride concentration
(> 60 mmol/l) – SWEAT TEST
• Or identification of two CF mutations – genotyping
• Or demonstration of abnormal nasal epithelial ion
transport (nasal potential difference)

54

Presenting features of CF

- chronic sinusitis
- nasal polyps
- repeated LRTI
- bronchiectasis
- Liver disease; portal hypertension; gallstones
- DIOS
- Steatorrhoea
- Abnormal sweat secretions
- Pancreatic insufficiency (malabsoprtion and DM)
- Finger clubbing
- Osteoporosis
- Male infertility
- Arthritis

Meconium ileus - bowel is blocked by sticky secretions, Signs of intestinal obstruction soon after birth with bilious vomiting, abdominal distension and delay in passing meconium.

55

Common complications of CF

1.Respiratory Infections
- Needs aggressive therapy with physio and
antibiotics +/- prophylactic Abx
2.Low Body Weight
- needs careful monitoring
? pancreatic insufficiency--> Creon (pancreatic enzyme replacement therapy)
- high calorie intake and often extra supplements
- may need NG or PEGf eeding
3.Distal Intestinal Obstruction Syndrome (DIOS)
- DIOS vs.constipation faecal obstruction in ileocaecum versus whole bowel
- Due to intestinal contents in the distal ileum and proximal colon (thick, dehydrated faeces)
-Often insufficient prescription of pancreatic
enzymes or non-compliance, also salt deficiency / hot weather
- Often presents with palpable right iliac fossa mass (faecal)
-Diagnosis: Symptoms; palpable RightIliacFossaMass,
AXR demonstrating faecal loading at junction of small
and large bowel
4. CF Related Diabetes

56

CF lifestyle advice advice

• No smoking
• Avoid other CF patients
• Avoid friends / relatives with colds / infections
• Avoid jacuzzis (pseudomonas)
• Clean and dry nebulisers thoroughly
• Avoid stables, compost or rotting vegetation – risk of
aspergillus fumigatus inhalation
• Annual influenza immunisation
• Sodium chloride tablets in hot weather / vigorous
exercise

57

Types of pneumothorax

1.Spontaneous
i.Primary (no lung disease) ii.Secondary (lung disease) 2.Traumatic
3.TENSION: emergency
4.Iatrogenic (e.g. post central line or pacemaker insertion)

58

Risk factors for pneumothorax

- Pre-existing lung disease
- Height
- Smoking/ Cannabis
- Diving
- Trauma/ Chest procedure
- Association with other conditions e.g. Marfan’s
syndrome

59

Management for pneumothorax

Primary – If symptomatic and rim of air >2cm on
CXR give O2 and aspirate. If unsuccessful consider re-aspiration or intercostal drain. Remove drain after full re-expansion / cessation of air leak.

Secondary – as above but lower threshold for ICD

If persistent air leak >5 days (bronchopleural
fistula) refer to thoracic surgeons

Discharge advice – No flying or diving until
resolved

60

Investigations for pleural effusion

USS guided pleural aspiration
- biochemistry (protein, pH, LDH)
- Cytology
- Microbiology

•CXR
•ECG
•Bloods: FBC, U&E’s, LFT’s, CRP, Bone profile, LDH, clotting
•ECHO (if suspect heart failure)
•Staging CT (with contrast) if suspect exudative cause

61

Indications for urgent chest drain for new effusion

underlying empyema (pH of pleural fluid <7.2 or visible pus on aspirate).

62

Causes of transudate effusion
- pleural protein <30g/L

Common:
" Heart failure
" Cirrhosis
" Hypoalbuminaemia (nephrotic syndrome or
peritoneal dialysis) Less common:
" Hypothyroidism, mitral stenosis, pulmonary embolism
Rare:
" Constrictive pericarditis, superior vena cava
obstruction, Meig’s syndrome

63

Causes of Exudate effusions
- pleural protein >30 g/L

Common:
" Malignancy
" Infections – parapneumonic, TB, HIV (kaposi’s) Less common:
" Inflammatory (rheumatoid arthritis, pancreatitis, benign asbestos effusion, Dressler’s, pulmonary infarction/pulmonary embolus), Lymphatic disorders, Connective tissue disease
Rare:
" Yellow nail syndrome, fungal infections, drugs

64

Lights criteria - and when is it used

If pleural fluid protein level between 25 and 35 g/L (i.e. borderline) use Light’s criteria
– exudate if one or more of the following:
– Pleural fluid/Serum protein >0.5
– Pleural fluid/Serum LDH >0.6
– Pleural fluid LDH > 2/3 of the upper limit of normal

65

Management of transudate

Often no diagnostic tap is required
• Treat the underlying cause
• If effusion resolves, stop or reduce treatment
• If effusion persists, then therapeutic
aspiration/drainage is required

66

Commonest type of pulmonary fibrosis

Usual Interstitial Pneumonia

67

Classical findings in UIP

Classical Findings:
• clubbing, reduced chest expansion
• Auscultation – fine inspiratory crepitations (like pulling Velcro slowly) – usually best heard basal / axillary areas
• Cardiovascular – may be features of pulmonary hypertension

68

Cause and clinical presentation of extrinsic allergic alveolitis

Inhalation of organic Ag to which the individual has been sensitised

–ACUTE – short period from exposure, 4-8 hrs. Usually reversible: spontaneously settle 1-3 days. Can recur.
–CHRONIC – chronic exposure (months – years). Less reversible

69

Define sarcoidosis

Multisystem inflammatory condition of unknown cause
• Non-caseating granulomas

70

Investigations for sarcoidosis

• PFTs: (obstructive until) fibrosis
• CXR: 4 stages
• Bloods: renal function, ACE, Calcium
• Urinary Calcium
• Cardiac involvement: ECG, 24 tape, ECHO, cardiac MRI • CT/MRI head: headaches – Neuro sarcoid

71

Treatment for Interstitial lung disease

• Occupational exposure – remove
• Drug associated – avoid
• Stop smoking
• ? N-Acetylcysteine ? Immunosuppressant ? Pirfenidone
• Transplantation
• Treatment of infections (atypical)
• Oxygen
• MDT
• Palliative care

72

Clinical features of lung cancer

Asymptomatic, incidental finding
• Any respiratory symptom/systemic deterioration
• Superior Vena Caval Obstruction
• Horner’s syndrome
• Metastatic disease – liver, adrenals (Addison’s),
bone, pleural, CNS
• Paraneoplastic – clubbing, hypercalcaemia,
anaemia, SIADH, Cushing’s syndrome, Lambert- Eaton myasthenic syndrome, thrombo-embolic disease

73

Risk factors for lunch cancer

• Large number of smoking pack years
• Airflow obstruction
• Increasing age
• Family history of lung cancer
• Exposure to other carcinogens, e.g. asbestos

74

WHO performance status

0 Normal - Fully active without restriction

1 Restricted in physically strenuous activity but
ambulatory and able to carry out light work e.g.,
light house work, office work

2 Ambulatory and capable of all self-care but
unable to carry out any work activities. Up and
about more than 50% of waking hours

3 Capable of only limited self-care, confined to
bed or chair more than 50% of waking hours

4 Completely disabled. Cannot self-care. Totally
confined to bed or chair

5 Dead

75

Investigations of lung cancer

Bloods – FBC, U&E, Calcium, LFT’s, INR
•CXR
• Staging CT – Spiral CT Thorax and Upper Abdo –
helps to stratify TNM stage
•PET (detect small mets)

Histology
• US guided neck node FNA for cytology if
lymphadenopathy
• Bronchoscopy – endobronchial, transbronchial,
endobronchial ultrasound (if mediastinal
lymphadenopathy)
• CT Biopsy
• Thoracoscopy if pleural effusion present

76

Treatment for lung cancer

• Curative surgery for stages I & II – assuming fit for surgery
• Surgery & adjuvant chemotherapy clinical trial for stage IIIa – assuming fit for surgery & chemo
• Chemotherapy – consider in patients with stage III/IV disease and PS 0-2
• Radiotherapy – curative (CHART = continuous hyperfractionated accelerated radiotherapy) for people not fit for surgery OR palliative
• Palliative Care
• Do nothing / watch & wait

77

Prognosis for SCLC

Rapid growth rate and almost always too extensive for surgery at time of diagnosis
• Mainstay of treatment is chemotherapy
• Also palliative radiotherapy
• Untreated – median survival is 4-12 weeks
• Combination chemotherapy – median survival 6- 15 months

78

Define Obstructive Sleep Apnoea

upper airway narrowing,
provoked by sleep, causing sufficient sleep fragmentation to result in significant daytime symptoms, usually excessive sleepiness

79

Pathophysiology of OSA

- Upper airway patency depends on dilator muscle activity. All muscles relax during sleep (including pharyngeal dilators).
- Some narrowing of the upper airway is normal
- Excessive narrowing can be due to either an
already small pharyngeal size during awake state which undergoes a normal degree of muscle relaxation during sleep causing critical narrowing OR excessive narrowing occurring with relaxation during sleep

80

Risk factors for OSA

- Fatty infiltration of pharyngeal tissues and external pressure from increased neck fat and/or muscle bulk
- Large tonsils
- Craniofacial abnormalities
- Extra submucosal tissue, e.g. myxoedema
- NMD - greater loss of dilator muscle tone, e.g. stroke, MND, myotonic dystrophy
- Muscle relaxants – sedatives, alcohol
- Increasing age

81

Clinical effects for OSA

- repetitive upper airway collapse, with arousal required to re-activate the pharyngeal dilators.
- associated hypoxia and hypercapnia -->corrected during the inter-apnoeic hyperventilatory period.
- Recurrent arousals lead to highly fragmented and unrefreshing sleep – snoring and apnoea attacks often witnessed by partner
- Excessive daytime sleepiness results (Epworth Sleepiness Scale score >9)
- With every arousal there is a rise in BP, often over 50 mmHg. It is not clear if this damages the CVS. There is also a rise in daytime BP.
- Nocturia
- Less common - Nocturnal sweating, reduced
libido, oesophageal reflux

82

Epworth sleepiness scale

Points for following:
0=would never doze,
1=slight chance,
2=moderate chance,
3=high chance

-Sitting & reading
- Watching TV
- Sitting in a public place, e.g. theatre
- Passenger in a car for an hour
- Lying down to rest in the afternoon
- Sitting & talking
- Sitting quietly after lunch without alcohol
- In a car, while stopped in traffic

83

Diagnosis of OSA

- Overnight oximetry alone
- Limited sleep study – oximetry, snoring, body
movement, heart rate, oronasal flow, chest/abdominal movements, leg movements – usual study of choice
- Full polysomnography – limited study plus EEG, EMG

84

Management of OSA

Given based on symptoms/quality of life – NOT on severity seen on sleep study

- Weight loss
- sleep decubitus rather than supine
- avoid/reduce evening alcohol intake

FOR SNORERS & MILD OSA:
- Mandibular advancement devices, consider
pharyngeal surgery as last resort
FOR SIGNIFICANT OSA:
- Nasal CPAP (upper airway splinted open with 10cm H20 This prevents airways collapse, sleep fragmentation, and ultimately daytime somnelence)
- consider gastroplasty/bypass, and rarely tracheostomy
FOR SEVERE OSA & CO2 RETENTION:
- May require a period of NIV prior to CPAP if
acidotic, but compensated CO2 may reverse with CPAP alone

85

Driving advice for OSA

- Tell all patients with OSA to NOT drive while sleepy; stop and have a nap. On diagnosis the patient should notify the DVLA
- The doctor can advise drivers to stop altogether (e.g. HGV drivers)

86

Action of salbutamol, salmeterol

ß2-selective adrenergic agonists
Increase cAMP in SMC’s resulting in relaxation and thus bronchodilation

87

SE of salbutamol, salmeterol

Tremor, headache, GI upset, palpitations, tachycardia, hypokalaemia

88

Action of Ipratropium/ Tiotropium

Muscarinic antagonist Decreases cGMP which affects intracellular calcium resulting in decreased SMC contractility

89

SE Ipratropium/ Tiotropium

Dry mouth, constipation, cough, headache

90

CI of Ipratropium/ Tiotropium

angle- closure glaucoma & Benign Prostatic Hypertrophy

91

Actino of aminophylline

Block phosphodiesterases resulting in decreased cAMP breakdown causing bronchodilation

Positive chronotropic and inotropic effects, diuretic action

92

SE and toxic effects aminophylline

Headache, GI upset, reflux, palpitations, dizziness
TOXIC - serious arrhythmias, seizures, N&V, hypotension

93

Action of inhaled steroids e.g. beclomethasone

Increase airway calibre by decreasing bronchial inflammation +/- modifying allergic reactions

94

SE of inhaled steroids e.g. beclomethasone

Cough, oral thrush, unpleasant taste, hoarseness

95

Advice after use inhaled steroids

good oral hygiene

96

Examples of corticosteroids

Prednisolone (PO), Hydrocortisone (IV/IM), Dexamethasone (PO/IV), Triamcinolone (IM)

97

Actions of corticosteoids

Supress inflammation, allergy & immune responses by altering gene transcription

98

SE of corticosteroids

Adrenal suppression (especially courses > 3 weeks), hyperglycaemia, psychosis, insomnia, indigestion, mood swings

Other Side Effects

Diabetes, cataracts, glaucoma, peptic ulceration, susceptibility to infections, osteoporosis, muscle wasting, skin thinning, Cushingoid appearance

99

Additional medication to prescribe with long-term steroids and patient information

May need PPI (reduce GORD), Bisphosphonates (bone protection) and steroid card.

100

MRC Dyspnoea Score

1 Not troubled by breathlessness except on strenuous exercise
2 Short of breath when hurrying or walking up a slight hill
3 Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace
4 Stops for breath after walking about 100m or after a few minutes on level ground
5 Too breathless to leave the house, or breathless when dressing or undressing

101

Management of chronic asthma - BTS guidelines

Assess symptoms, measure lung function, check inhaler technique and adherence, adjust dose, update self-management plan
STEPWISE
Short acting β2 agonists as required – consider moving up if using three doses a week or more
1) Low-dose ICS
2) + inhaled LABA
3) - No response to LABA – stop LABA and consider
increased dose of ICS
- If benefit from LABA but control still inadequate- continue LABA and increase ICS to medium dose
- If benefit from LABA but control still inadequate
- continue LABA and ICS and consider trial of other therapy - LTRA, SR theophylline, LAMA
4) Increasing ICS up to high dose
- Addition of a fourth drug, eg LTRA, SR theophylline, beta agonist tablet, LAMA
- Refer to specialist care
5) Use daily steroid tablet and Maintain high-dose ICS

102

Management of chronic COPD - stable management

General
- smoking cessation advice
- annual influenza vaccination
- one-off pneumococcal vaccination

1) SABA or SAMA
2) FEV1 > 50% - LABA or LAMA e.g. tiotropium
- FEV1 < 50% - LABA + ICS or: LAMA
3) Then LABA +ICS
- + LAMA

- Mucolytics = productive cough

103

Management of pulmonary oedema

 Sit up and give high-flow O2
 Morphine 2.5mg IV (± metoclopramide 10mg IV)
 Frusemide 120-250mg IV over 1h
 GTN spray ± ISMN IVI (unless SBP <90)
 If no response consider:
 CPAP
 Haemofiltration / haemodialysis ± venesection